Literature DB >> 32838473

The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation.

Tatjana S Potpara1,2, Gregory Y H Lip1,3,4, Carina Blomstrom-Lundqvist5, Giuseppe Boriani6, Isabelle C Van Gelder7, Hein Heidbuchel8, Gerhard Hindricks9, Alan John Camm10.   

Abstract

Atrial fibrillation (AF) is a complex condition requiring holistic management with multiple treatment decisions about optimal thromboprophylaxis, symptom control (and prevention of AF progression), and identification and management of concomitant cardiovascular risk factors and comorbidity. Sometimes the information needed for treatment decisions is incomplete, as available classifications of AF mostly address a single domain of AF (or patient)-related characteristics. The most widely used classification of AF based on AF episode duration and temporal patterns (that is, the classification to first-diagnosed, paroxysmal, persistent/long-standing persistent, and permanent AF) has contributed to a better understanding of AF prevention and treatment but its limitations and the need for a multidimensional AF classification have been recognized as more complex treatment options became available. We propose a paradigm shift from classification toward a structured characterization of AF, addressing specific domains having treatment and prognostic implications to become a standard in clinical practice, thus aiming to streamline the assessment of AF patients at all health care levels facilitating communication among physicians, treatment decision-making, and optimal risk evaluation and management of AF patients. Specifically, we propose the 4S-AF structured pathophysiology-based characterization (rather than classification) scheme that includes four AF- and patient-related domains-Stroke risk, Symptoms, Severity of AF burden, and Substrate severity-and provide a hypothetical model for the use of 4S-AF characterization scheme to aid treatment decision making concerning the management of patients with AF in clinical practice. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 32838473     DOI: 10.1055/s-0040-1716408

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  17 in total

Review 1.  Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Benjamin J R Buckley; Deirdre A Lane; Peter Calvert; Juqian Zhang; David Gent; C Daniel Mullins; Paul Dorian; Shun Kohsaka; Stefan H Hohnloser; Gregory Y H Lip
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

2.  Rhythm- or rate-control strategies according to 4S-AF characterization scheme and long-term outcomes in atrial fibrillation patients: the FAMo (Fibrillazione Atriale in Modena) cohort.

Authors:  Gregory Y H Lip; Giuseppe Boriani; Vincenzo L Malavasi; Marco Vitolo; Jacopo Colella; Francesca Montagnolo; Marta Mantovani; Marco Proietti; Tatjana S Potpara
Journal:  Intern Emerg Med       Date:  2021-12-02       Impact factor: 5.472

3.  Preventing esophageal complications from atrial fibrillation ablation: A review.

Authors:  Lisa W M Leung; Zaki Akhtar; Mary N Sheppard; John Louis-Auguste; Jamal Hayat; Mark M Gallagher
Journal:  Heart Rhythm O2       Date:  2021-09-22

4.  Atrial fibrillation.

Authors: 
Journal:  Nat Rev Dis Primers       Date:  2016-03-31       Impact factor: 65.038

5.  Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial.

Authors:  Wern Yew Ding; José Miguel Rivera-Caravaca; Francisco Marin; Vanessa Roldán; Gregory Y H Lip
Journal:  J Thromb Thrombolysis       Date:  2022-04-15       Impact factor: 5.221

6.  Atrial Fibrillation and Oral Health.

Authors:  Amaar Hassan; Gregory Yh Lip; Laurent Fauchier; Rebecca V Harris
Journal:  Arrhythm Electrophysiol Rev       Date:  2021-04

Review 7.  Optimizing indices of atrial fibrillation susceptibility and burden to evaluate atrial fibrillation severity, risk and outcomes.

Authors:  Giuseppe Boriani; Marco Vitolo; Igor Diemberger; Marco Proietti; Anna Chiara Valenti; Vincenzo Livio Malavasi; Gregory Y H Lip
Journal:  Cardiovasc Res       Date:  2021-06-16       Impact factor: 13.081

8.  Non-alcoholic Fatty Liver Disease and the Risk of Incident Atrial Fibrillation in Young Adults: A Nationwide Population-Based Cohort Study.

Authors:  JungMin Choi; So-Ryoung Lee; Eue-Keun Choi; Hyo-Jeong Ahn; Soonil Kwon; Sang-Hyeon Park; HuiJin Lee; Jaewook Chung; MinJu Han; Seung-Woo Lee; Kyung-Do Han; Seil Oh; Gregory Y H Lip
Journal:  Front Cardiovasc Med       Date:  2022-03-23

Review 9.  Imaging Techniques for the Study of Fibrosis in Atrial Fibrillation Ablation: From Molecular Mechanisms to Therapeutical Perspectives.

Authors:  Francesco De Sensi; Diego Penela; David Soto-Iglesias; Antonio Berruezo; Ugo Limbruno
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

10.  Apixaban versus PhenpRocoumon: Oral AntiCoagulation plus antiplatelet tHerapy in patients with Acute Coronary Syndrome and Atrial Fibrillation (APPROACH-ACS-AF): Rationale and design of the prospective randomized parallel-group, open-label, blinded-endpoint, superiority, multicenter-trial of a triple therapy versus a dual therapy in patients with Atrial Fibrillation and Acute Coronary Syndrome undergoing coronary stenting.

Authors:  Lisa Riesinger; Claudia Strobl; David M Leistner; Tommaso Gori; Ibrahim Akin; Michael Mehr; Antonia Kellnar; Amir A Mahabadi; Harilaos Bogossian; Michael Block; Frank Edelmann; Nikolaus Sarafoff; Dirk Sibbing; Hüseyin Ince; Tienush Rassaf; Ulrich Mansmann; Julinda Mehilli; Stefan Kääb; Jörg Hausleiter; Steffen Massberg; Reza Wakili
Journal:  Int J Cardiol Heart Vasc       Date:  2021-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.